Journal «Angiology and Vascular Surgery» •
2021 • VOLUME 27 • №1
Results of comprehensive conservative treatment of patients with no-option chronic limb-threatening ischaemia
Chervyakov Yu.V.1, Ha H.N.2
1) Department of Surgery of the Institute of Postgraduate Education, Yaroslavl State Medical University, Yaroslavl, Russia
2) Department of Cardiovascular Surgery, Military Central Hospital № 108, Hanoi, Vietnam
Objective. The study was aimed at comparing efficacy of conventional conservative therapy and comprehensive treatment including a plasmid VEGF-165-gene therapy drug in "no-option" chronic limb-threatening ischaemia with different prevalence of trophic ulcers and infection during a 1-year follow-up period.
Patients and methods. A total of 101 patients (54% being men and 46% women, mean age 69 years) with "no-option" chronic limb-threatening ischaemia underwent comprehensive conservative treatment. They were subdivided into 4 groups according to the WIFI classification: WIFI 130 (n=38), 131 (n=23), 230 (n=16), 231 (n=24). The control group patients (n=58) received standard treatment using a PGE1 analogue (Vasaprostan) and the study group patients (n=43) underwent standard conservative treatment (SCT) in combination with gene therapy. The end points of the study were as follows: major amputation rate, amputation-free survival, total mortality, and ulcer healing rate during a 1-year of follow up.
Results. Major amputation rate in the control and study groups amounted to 35 and 28% (p=0.48), respectively, with amputation-free survival of 53 and 63% (p=0.35), total mortality of 21 and 12% (p=0.23), ulcer healing rate of 31 and 51% (p=0.04), respectively. The WIfI classification made it possible to single out a subgroup of patients (WIfI combination 130) yielding other statistically significant results: major amputation rate 27% and 0% (p=0.03), amputation-free survival 59 and 94% (p=0.025), ulcer healing rate 50 and 88% (p=0.016), respectively.
Conclusions. Using plasmid-based VEGF-165 gene therapy in the subgroup with the WIfI combination 130 decreases the major amputation rate (p=0.03), increases amputation-free survival (p=0.025) and promotes ulcer healing (p=0.016) compared with the standard therapy during 1-year follow up. No significant differences in the compared groups were revealed by all endpoints of the study for other combinations analysed. The total mortality rate in patients with limb-threatening ischaemia does not depend on either the initial severity of ulcer or the selcted methods of conservative treatment.
KEY WORDS: chronic limb-threatening ischaemia, plasmid-based VEGF-165 gene drug, WIfI classification, conservative treatment.
P. 32
ARCHIVES MAGAZINE
2021 (Vol.27)
2020 (Vol.26)
2019 (Vol.25)
2018 (Vol.24)
2017 (Vol.23)
2016 (Vol.22)
2015 (Vol.21)
2014 (Vol.20)
2013 (Vol.19)
2012 (Vol.18)
2011 (Vol.17)
2010 (Vol.16)
2009 (Vol.15)
2008 (Vol.14)
2007 (Vol.13)
2006 (Vol.12)
2005 (Vol.11)
2004 (Vol.10)
2001 (Vol.7)
2000 (Vol.6)
1999 (Vol.5)
1998 (Vol.4)
1997 (Vol.3)